Drug Profile
DMVT 503
Alternative Names: DMVT-503; RVT-503Latest Information Update: 06 Jul 2022
Price :
$50
*
At a glance
- Originator Dermavant Sciences
- Class Antiacnes; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 28 Jun 2022 Discontinued (due to company-wide cost optimization and pipeline reprioritization) - Preclinical for Acne in Switzerland (Topical)
- 06 May 2022 DMVT 503 is still in preclinical trials for Acne in Switzerland (Roivant Sciences pipeline, May 2022)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Acne in Switzerland (Topical)